Calcitriol
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Calcitriol: active vitamin D hormone → obsolete vitamin D deficiency
One-Sentence Summary
Calcitriol is the active form of vitamin D, a hormone that regulates calcium and phosphate balance. The TxGNN model predicts it may be relevant for obsolete vitamin D deficiency, but no clinical trials and no publications directly study this disease in the data compiled for this report, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | obsolete vitamin D deficiency |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Calcitriol is the biologically active form of vitamin D (1,25-dihydroxyvitamin D3). It acts on the vitamin D receptor to raise intestinal absorption of calcium and phosphate and to regulate bone mineral metabolism.
Because calcitriol is the active hormone itself, a link to vitamin D deficiency is biologically plausible and likely explains the very high score. However, the disease term is flagged as obsolete, and the prediction largely restates the drug’s known physiology rather than offering a novel repurposing signal. In practice, deficiency of the precursor vitamin is usually corrected with native vitamin D, while calcitriol is typically reserved for situations where activation is impaired.
Clinical Trial Evidence
Currently no related clinical trials registered for this predicted indication.
Literature Evidence
Currently no related literature available for this predicted indication.
India Market Information
Calcitriol is marketed in India. The records compiled for this report show 20 valid single-ingredient licences and none cancelled; the list may be partial. The licence records carry no indication text. Available forms:
| Route | Dosage Forms |
|---|---|
| Oral | Strips of 15 or 10 soft gelatin capsules; strips of 10 tablets |
| Injectable | 1 ml ampoule; packet of 6 injections |
Safety Considerations
- Drug Interactions (339 interactions recorded; examples):
- Major: cholecalciferol, calcifediol, burosumab
- Moderate: thiazide diuretics (hydrochlorothiazide, chlorothiazide, chlorthalidone, bendroflumethiazide), enzyme-inducing anticonvulsants and barbiturates (carbamazepine, fosphenytoin, amobarbital, butalbital, butabarbital), bile-acid binders (cholestyramine, colesevelam, colestipol), aluminium hydroxide, digoxin and digitoxin, topical calcipotriol
Please refer to the package insert for warnings and contraindications, which were not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high score but no supporting trials or literature, and the disease term is obsolete. It restates calcitriol’s known physiology rather than a new use, so the evidence level is L5.
To proceed, the following is needed:
- Clarify which current disease term replaces the obsolete one (e.g., vitamin D deficiency vs. impaired vitamin D activation)
- Studies directly addressing calcitriol in the target condition
- Mechanism-of-action data and package insert warnings and contraindications
- Calcium, phosphate and PTH monitoring plan, given the hypercalcaemia risk and the major interactions with other vitamin D products
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.